Is local radiotherapy a viable option for patients with an opening of the ventricles during surgical resection of brain metastases?
Brain metastases
Hypofractionated stereotactic radiotherapy
Leptomeningeal disease
Local radiotherapy
Ventricular opening
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
10 Dec 2020
10 Dec 2020
Historique:
received:
03
08
2020
accepted:
06
12
2020
entrez:
11
12
2020
pubmed:
12
12
2020
medline:
1
9
2021
Statut:
epublish
Résumé
Local hypofractionated stereotactic radiotherapy (HFSRT) of the resection cavity is emerging as the standard of care in the treatment of patients with a limited number of brain metastases as it warrants less neurological impairment compared to whole brain radiotherapy. In periventricular metastases surgical resection can lead to an opening of the ventricles and subsequently carries a potential risk of cerebrospinal tumour cell dissemination. The aim of this study was to assess whether local radiotherapy of the resection cavity is viable in these cases. From our institutional database we analyzed the data of 125 consecutive patients with resected brain metastases treated in our institution with HFSRT between 2009 and 2017. The incidence of LMD, overall survival (OS), local recurrence (LC) and distant recurrence were evaluated depending on ventricular opening (VO) during surgery. From all 125 patients, the ventricles were opened during surgery in 14 cases (11.2%). None of the patients with VO and 7 patients without VO during surgery developed LMD (p = 0.371). OS (p = 0.817), LC (p = 0.524) and distant recurrence (p = 0.488) did not differ in relation to VO during surgical resection. However, the incidence of distant intraventricular recurrence was slightly increased in patients with VO (14.3% vs. 2.7%, p < 0.01). VO during neurosurgical resection did not affect the outcome after HFSRT of the resection cavity in patients with brain metastases. Particularly, the incidence of LMD was not increased in patients receiving local HFSRT after VO. HFSRT can therefore be offered independently of VO as a local treatment of tumor bed after resection of brain metastases.
Sections du résumé
BACKGROUND
BACKGROUND
Local hypofractionated stereotactic radiotherapy (HFSRT) of the resection cavity is emerging as the standard of care in the treatment of patients with a limited number of brain metastases as it warrants less neurological impairment compared to whole brain radiotherapy. In periventricular metastases surgical resection can lead to an opening of the ventricles and subsequently carries a potential risk of cerebrospinal tumour cell dissemination. The aim of this study was to assess whether local radiotherapy of the resection cavity is viable in these cases.
METHODS
METHODS
From our institutional database we analyzed the data of 125 consecutive patients with resected brain metastases treated in our institution with HFSRT between 2009 and 2017. The incidence of LMD, overall survival (OS), local recurrence (LC) and distant recurrence were evaluated depending on ventricular opening (VO) during surgery.
RESULTS
RESULTS
From all 125 patients, the ventricles were opened during surgery in 14 cases (11.2%). None of the patients with VO and 7 patients without VO during surgery developed LMD (p = 0.371). OS (p = 0.817), LC (p = 0.524) and distant recurrence (p = 0.488) did not differ in relation to VO during surgical resection. However, the incidence of distant intraventricular recurrence was slightly increased in patients with VO (14.3% vs. 2.7%, p < 0.01).
CONCLUSION
CONCLUSIONS
VO during neurosurgical resection did not affect the outcome after HFSRT of the resection cavity in patients with brain metastases. Particularly, the incidence of LMD was not increased in patients receiving local HFSRT after VO. HFSRT can therefore be offered independently of VO as a local treatment of tumor bed after resection of brain metastases.
Identifiants
pubmed: 33303000
doi: 10.1186/s13014-020-01725-x
pii: 10.1186/s13014-020-01725-x
pmc: PMC7730779
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
276Références
Cancer Med. 2018 Jun;7(6):2350-2359
pubmed: 29745035
Surg Neurol Int. 2013 May 02;4(Suppl 4):S265-88
pubmed: 23717798
J Neurooncol. 1997 May;32(3):215-23
pubmed: 9049883
Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):943-8
pubmed: 22494581
Radiat Oncol. 2018 Jul 28;13(1):138
pubmed: 30055640
J Neurosurg Sci. 2016 Sep;60(3):357-66
pubmed: 27071010
Neurosurg Clin N Am. 2003 Oct;14(4):593-606
pubmed: 15024803
Curr Oncol Rep. 2019 Jul 4;21(8):73
pubmed: 31270629
J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):225-7
pubmed: 10071105
J Neurosurg. 2014 Dec;121 Suppl:26-34
pubmed: 25434934
Sci Rep. 2015 Dec 04;5:17758
pubmed: 26635136
Clin Neurol Neurosurg. 2003 Dec;106(1):9-15
pubmed: 14643909
J Neurooncol. 2015 May;123(1):103-11
pubmed: 25862006
Front Oncol. 2018 Aug 31;8:342
pubmed: 30234013
Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):764-771
pubmed: 31785338
Neurosurg Clin N Am. 2011 Jan;22(1):67-78, vii
pubmed: 21109151
J Neurooncol. 2016 May;127(3):581-7
pubmed: 26830090
Front Oncol. 2018 May 24;8:161
pubmed: 29881714
Lancet Oncol. 2017 Aug;18(8):1040-1048
pubmed: 28687375
J Neurosurg. 2012 May;116(5):984-93
pubmed: 22339161
Radiat Oncol. 2017 Jun 24;12(1):106
pubmed: 28646895
Neurosurgery. 2009 Apr;64(4):664-74; discussion 674-6
pubmed: 19197219
J Neurosurg. 2008 Feb;108(2):248-57
pubmed: 18240919
Am Soc Clin Oncol Educ Book. 2015;:e99-104
pubmed: 25993245
Cancer Med. 2018 Jun;7(6):2319-2327
pubmed: 29696815
J Neurooncol. 2012 Feb;106(3):601-10
pubmed: 21879395
Ann Oncol. 2017 Jul 1;28(suppl_4):iv84-iv99
pubmed: 28881917
J Clin Oncol. 2011 Jan 10;29(2):134-41
pubmed: 21041710
Lancet Oncol. 2017 Aug;18(8):1049-1060
pubmed: 28687377
Surg Neurol Int. 2016 Oct 20;7:92
pubmed: 27857856
Neurosurgery. 2019 Nov 1;85(5):E860-E869
pubmed: 31173150
Strahlenther Onkol. 2019 Mar;195(3):207-217
pubmed: 30386864
J Neurooncol. 2014 Dec;120(3):657-63
pubmed: 25189789
Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):436-442
pubmed: 29157748
Strahlenther Onkol. 2016 Jun;192(6):368-76
pubmed: 26964777
J Clin Neurosci. 2018 Mar;49:48-55
pubmed: 29248376
J Neurooncol. 2018 Sep;139(2):449-454
pubmed: 29749569
JAMA. 1998 Nov 4;280(17):1485-9
pubmed: 9809728
Cancer Commun (Lond). 2019 Nov 9;39(1):73
pubmed: 31706337
Radiat Oncol. 2018 May 16;13(1):96
pubmed: 29769103
Cureus. 2016 Apr 19;8(4):e575
pubmed: 27226936
Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1179-1189
pubmed: 28974415
J Neurosurg. 2010 May;112(5):1046-55
pubmed: 19663549